Defilade Capital Management, L.P.
13F Reported Value
ⓘ$746.9M
Holdings
39
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Defilade Capital Management, L.P. disclosed 39 positions worth $746.9M in its Form 13F-HR for Q2 2026, led by $LLY (ELI LILLY & Co) at 6.3% of the equity portfolio, followed by $PFE and $VEEV. During the quarter the fund opened 19 new positions and exited 11 — including a new stake in $VEEV and a full exit from $HSIC. The portfolio is most concentrated in Healthcare (90.9% of disclosed assets). All figures are sourced directly from Defilade Capital Management, L.P.’s Form 13F-HR filing with the SEC under CIK 2088557.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 87.5#2
Quality
$46.9M39,086 sh - 62.0#736
Quality
$42.7M1,771,743 sh - 77.6#64
Quality
$42.0M236,709 sh - 58.2
Quality
$39.0M682,005 sh - 35.4
Quality
$35.4M433,699 sh - 50.1
Quality
$31.1M1,459,380 sh - 39.4
Quality
$30.0M281,838 sh - 65.7
Quality
$27.3M317,426 sh - 71.3
Quality
$26.9M176,932 sh - 65.1
Quality
$26.0M51,934 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 ELI LILLY & Co$LLY | 87.5#2 | $46.9M | 39,086 |
 PFIZER INC$PFE | 62.0#736 | $42.7M | 1,771,743 |
 VEEVA SYSTEMS INC$VEEV | 77.6#64 | $42.0M | 236,709 |
 BIOMARIN PHARMACEUTICAL INC$BMRN | 58.2 | $39.0M | 682,005 |
 PTC THERAPEUTICS, INC.$PTCT | 35.4 | $35.4M | 433,699 |
 BAXTER INTERNATIONAL INC$BAX | 50.1 | $31.1M | 1,459,380 |
 INSMED Inc$INSM | 39.4 | $30.0M | 281,838 |
 ZIMMER BIOMET HOLDINGS, INC.$ZBH | 65.7 | $27.3M | 317,426 |
 INSULET CORP$PODD | 71.3 | $26.9M | 176,932 |
 THERMO FISHER SCIENTIFIC INC.$TMO | 65.1 | $26.0M | 51,934 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Defilade Capital Management, L.P.'s 39 positions.
Showing top 10 of 39 holdings.
Sector Allocation
Healthcare
$678.9M
Technology
$68.0M
Full Holdings — Defilade Capital Management, L.P. (Q2 2026)
All 39 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $LLY | ELI LILLY & Co | $46.9M | 6.3% | +89% | 87.5 |
| 2 | $PFE | PFIZER INC | $42.7M | 5.7% | +21% | 62 |
| 3 | $VEEV | VEEVA SYSTEMS INC | $42.0M | 5.6% | NEW | 77.6 |
| 4 | $BMRN | BIOMARIN PHARMACEUTICAL INC | $39.0M | 5.2% | NEW | 58.2 |
| 5 | $PTCT | PTC THERAPEUTICS, INC. | $35.4M | 4.7% | +15% | 35.4 |
| 6 | $BAX | BAXTER INTERNATIONAL INC | $31.1M | 4.2% | NEW | 50.1 |
| 7 | $INSM | INSMED Inc | $30.0M | 4.0% | +45% | 39.4 |
| 8 | $ZBH | ZIMMER BIOMET HOLDINGS, INC. | $27.3M | 3.7% | -45% | 65.7 |
| 9 | $PODD | INSULET CORP | $26.9M | 3.6% | NEW | 71.3 |
| 10 | $TMO | THERMO FISHER SCIENTIFIC INC. | $26.0M | 3.5% | NEW | 65.1 |
| 11 |  $ABT | ABBOTT LABORATORIES | $25.9M | 3.5% | NEW | 65.5 |
| 12 |  $ASND | Ascendis Pharma A/S | $25.3M | 3.4% | +83% | 44.8 |
| 13 |  $SOLV | Solventum Corp | $24.4M | 3.3% | NEW | 55.2 |
| 14 |  $MDT | Medtronic plc | $23.7M | 3.2% | NEW | 68.7 |
| 15 |  $ELAN | Elanco Animal Health Inc | $21.3M | 2.9% | -7% | 48.7 |
| 16 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $20.3M | 2.7% | NEW | 26.9 |
| 17 |  $NVST | Envista Holdings Corp | $19.1M | 2.6% | NEW | 54.9 |
| 18 |  $RVMD | Revolution Medicines, Inc. | $15.5M | 2.1% | -74% | — |
| 19 |  $ICUI | ICU MEDICAL INC/DE | $15.5M | 2.1% | -58% | 49 |
| 20 |  $COGT | Cogent Biosciences, Inc. | $15.2M | 2.0% | +12% | — |
| 21 |  $LNTH | Lantheus Holdings, Inc. | $14.7M | 2.0% | -47% | 61.1 |
| 22 |  $OCUL | OCULAR THERAPEUTIX, INC | $14.6M | 2.0% | +0% | 8.4 |
| 23 |  $ELDN | Eledon Pharmaceuticals, Inc. | $13.9M | 1.9% | -1% | — |
| 24 |  $TYRA | Tyra Biosciences, Inc. | $12.0M | 1.6% | NEW | — |
| 25 |  $OLMA | Olema Pharmaceuticals, Inc. | $11.6M | 1.6% | -39% | — |
| 26 |  $ORIC | Oric Pharmaceuticals, Inc. | $11.3M | 1.5% | +24% | — |
| 27 |  $LRMR | Larimar Therapeutics, Inc. | $11.2M | 1.5% | NEW | — |
| 28 |  $GMED | GLOBUS MEDICAL INC | $11.0M | 1.5% | -61% | 79.5 |
| 29 |  $ENOV | Enovis CORP | $11.0M | 1.5% | NEW | 39.5 |
| 30 |  $EVMN | Evommune, Inc. | $10.5M | 1.4% | +17% | 14.9 |
| 31 |  $TFX | TELEFLEX INC | $10.2M | 1.4% | NEW | 37.5 |
| 32 |  $DNLI | Denali Therapeutics Inc. | $10.1M | 1.4% | -71% | — |
| 33 |  $GKOS | GLAUKOS Corp | $9.3M | 1.2% | NEW | 40.5 |
| 34 |  $STAA | STAAR SURGICAL CO | $9.2M | 1.2% | NEW | 28.6 |
| 35 |  $PACS | PACS Group, Inc. | $9.2M | 1.2% | -64% | 71.2 |
| 36 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $9.0M | 1.2% | NEW | 25.5 |
| 37 |  $LIVN | LivaNova PLC | $8.8M | 1.2% | NEW | — |
| 38 |  $BDTX | Black Diamond Therapeutics, Inc. | $3.1M | 0.4% | NEW | 37.2 |
| 39 |  $MREO | Mereo BioPharma Group plc | $2.4M | 0.3% | +0% | — |
New Positions (19)
$VEEV VEEVA SYSTEMS INC$42.0M$BMRN BIOMARIN PHARMACEUTICAL INC$39.0M$BAX BAXTER INTERNATIONAL INC$31.1M$PODD INSULET CORP$26.9M$TMO THERMO FISHER SCIENTIFIC INC.$26.0M$ABT ABBOTT LABORATORIES$25.9M$SOLV Solventum Corp$24.4M$MDT Medtronic plc$23.7M$AGIO AGIOS PHARMACEUTICALS, INC.$20.3M$NVST Envista Holdings Corp$19.1M$TYRA Tyra Biosciences, Inc.$12.0M$LRMR Larimar Therapeutics, Inc.$11.2M$ENOV Enovis CORP$11.0M$TFX TELEFLEX INC$10.2M$GKOS GLAUKOS Corp$9.3M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Defilade Capital Management, L.P. including:
Track Defilade Capital Management, L.P.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Defilade Capital Management, L.P. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Defilade Capital Management, L.P.
13F Pro is an AI hedge fund tracker and stock research platform. For Defilade Capital Management, L.P. (SEC CIK: 2088557), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Defilade Capital Management, L.P.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.